Calcium, Vitamin D, and Risk for Colorectal Adenoma
Dependency on Vitamin D Receptor BsmI Polymorphism and Nonsteroidal Anti-Inflammatory Drug Use?1
- Sonia M. Boyapati,
- Roberd M. Bostick2,
- Katherine A. McGlynn,
- Michael F. Fina,
- Walter M. Roufail,
- Kim R. Geisinger,
- Michael Wargovich,
- Ann Coker and
- James R. Hebert
- Center for Health Services Research, Vanderbilt University, Nashville, Tennessee [S. M. B.]; Departments of Family and Preventive Medicine [R. M. B.] and Pathology [M. W.], School of Medicine, and Department of Epidemiology and Biostatistics, Norman J. Arnold School of Public Health [R. M. B., J. R. H.], University of South Carolina, Columbia, South Carolina; National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, Maryland [K. A. M.]; Forsyth Medical Specialists, PA, Winston-Salem, North Carolina [M. F. F.]; Wake Forest University, Winston-Salem, North Carolina [W. M. R., K. R. G.]; and School of Public Health, University of Texas, Houston, Texas [A. C.]
Abstract
Previous epidemiological studies have been inconclusive in demonstrating an inverse association among calcium, vitamin D, and risk for colorectal adenoma. The purpose of this analysis was to evaluate the associations among calcium and vitamin D and risk for incident, sporadic colorectal adenoma according to the vitamin D receptor BsmI polymorphism and nonsteroidal anti-inflammatory drug (NSAID) use. We analyzed data from a colonoscopy-based case-control study (n = 177 cases, 228 controls) conducted in North Carolina between 1995 and 1997. Adjusted odds ratios (ORs) comparing participants in the highest to those in the lowest tertiles of total calcium and vitamin D intakes were 0.64 [95% confidence interval (CI), 0.35–1.15], Ptrend = 0.14 and 0.69 (95% CI, 0.41–1.18), and Ptrend = 0.19, respectively. Adjusted ORs for those in the upper tertile of total calcium intake relative to those in the lower were 0.25 (95% CI, 0.08–0.80) among those who had a Bb genotype, 0.57 (95% CI, 0.18–1.82) among those who had a bb genotype, and 0.36 (95% CI, 0.15–0.85) among those who did not take NSAIDs. The ORs for the highest tertile of calcium intake was 0.05 (95% CI, 0.01–0.41), Ptrend < 0.01 among those who were Bb and did not take NSAIDs, and 0.16 (95% CI, 0.02–1.36), Ptrend = 0.47 among those who were bb and did not take NSAIDs. These data support the hypotheses that higher calcium intakes may decrease risk for colorectal neoplasms, and that such a relationship is more readily detectable among those who do not take NSAIDs, and may be strongest among those who have at least one vitamin D receptor BsmI b allele.
Footnotes
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
↵1 Supported in part by grant R01 CA66539 from the National Cancer Institute (to R. M. B.).
-
↵2 To whom requests for reprints should be addressed, at Division of Population Studies, 15 Medical Park, Suite 301, Columbia, SC 29203. Phone: (803) 434-1613; Fax: (803) 434-1626; E-mail: rbostick{at}gw.mp.sc.edu
-
↵3 The abbreviations used are: 1,25(OH)2D3, 1,25-dihydroxycholecalciferol; VDR, vitamin D receptor; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio; CI, confidence interval; FFQ, food frequency questionnaire.
-
- Accepted April 1, 1903.
- Received October 30, 1902.
- Revision received March 21, 1903.
